Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Sp1 transcription factor binding to DNA is a target for gene transcription inhibitors.
• Distinguishing direct Sp1 inhibition from indirect effects via cellular pathways is crucial.
• Sp3 protein shares binding sites with Sp1 and may modulate its activity.

Purpose of the Study:

• To differentiate direct Sp1-DNA binding inhibition from indirect effects on transcription.
• To assess Sp3 protein's ability to inhibit Sp1-activated transcription.
• To evaluate the specificity of bisanthracycline WP631 in inhibiting Sp1-mediated transcription.

Main Methods:

• Utilized a reporter gene system with wild-type and mutated GLUT1 promoters (wtGLUT1, mut2GLUT1) linked to CAT.
• Overexpressed Sp1 and Sp3 transcription factors in transiently transfected Jurkat T lymphocytes.
• Assayed bisanthracycline WP631 for transcription inhibition in transfected cells.

Main Results:

• Sp3 protein was shown to inhibit Sp1-activated transcription.
• The bisanthracycline WP631 demonstrated specific inhibition of transcription in Jurkat T lymphocytes.
• The mut2GLUT1 promoter facilitated discrimination between WP631 and Sp3 effects.

Conclusions:

• Sp3 protein can inhibit Sp1-activated transcription, suggesting a role in gene regulation.
• Bisanthracycline WP631 specifically inhibits Sp1-activated transcription in vivo.
• The study provides insights into differentiating direct and indirect mechanisms of transcription inhibition.